News Releases :: Sutro Biopharma, Inc. (STRO)

Apr 27, 2023 4:30 pm EDT

Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer

Apr 18, 2023 1:30 pm EDT

Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023

Mar 30, 2023 4:30 pm EDT

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones

Mar 17, 2023 4:01 pm EDT

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 1, 2023 8:00 am EST

Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference

Feb 28, 2023 8:00 am EST

Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer

Feb 17, 2023 4:01 pm EST

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 9, 2023 4:05 pm EST

Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer

Jan 4, 2023 8:00 am EST

Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

Dec 21, 2022 8:00 am EST

Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer